Scott W Woods, MD
Yale University
9
9
8
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+1 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (9)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Michael B Gill
Power Life Sciences Inc.
Shared therapeutic areas:
Sabine Hazan, MD
ProgenaBiome
Shared therapeutic areas:
Kwasi Donyina, Ph.D.
GAAD Medical Research Institute Inc.
Shared therapeutic areas:
Urielle Desalbres
Assistance Publique Hôpitaux de Marseille
Shared therapeutic areas:
Ken Nedd, M.D.
GAAD Medical Research Institute Inc.
Shared therapeutic areas:
Elliot Stein, Ph.D.
National Institute on Drug Abuse (NIDA)
Shared therapeutic areas:
Worked with same sponsors:
Carlos A Zarate, M.D.
National Institute of Mental Health (NIMH)
Shared therapeutic areas:
Worked with same sponsors:
emilie garrido pradalie
APHM
Shared therapeutic areas:
Ali MA Ismail, lecturer
Cairo University
Shared therapeutic areas:
Jean-Olivier ARNAUD, Director
Assistance Publique Hôpitaux de Marseille
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (9)
Showing 9 of 9 trials
Prevalence of Diabetes Mellitus Among Patients Treated With Atypical and Conventional Antipsychotics
Effectiveness of Atypical Versus Conventional Antipsychotics in Treating Schizophrenia
Aripiprazole Treatment of Prodromal Patients
Levetiracetam Treatment of Tardive Dyskinesia
Glycine vs Placebo for the Schizophrenia Prodrome
Ethyl-EPA Treatment of Prodromal Patients
Randomized Controlled Trial of Aspirin vs Placebo in the Treatment of Pre-psychosis
All 9 trials loaded